

AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-20 (Canceled)

21. (new) An isolated antibody or antibody fragment which specifically binds an isolated mammalian protein having anti-angiogenic activity and that is a receptor for an N-terminal fragment of plasminogen comprising kringle domains 1-4 and/or 5 wherein said protein does not cleave plasminogen kringle domains and wherein said protein comprises an amino acid sequence having 80% sequence homology or greater to SEQ ID NO: 4.
22. (new) An isolated antibody or antibody fragment which specifically binds an isolated mammalian protein having anti-angiogenic activity and that is a receptor for an N-terminal fragment of plasminogen comprising kringle domains 1-4 and/or 5 wherein said protein does not cleave plasminogen kringle domains and wherein said protein comprises SEQ ID NO: 4.
23. (new) An isolated antibody or antibody fragment according to claim 21, wherein said protein has a sequence homology equal to or greater than 80% to SEQ ID NO: 2 or 3.
24. (new) An isolated antibody or antibody fragment according to claim 22, wherein said protein has a sequence homology equal to or greater than 80% to SEQ ID NO: 2 or 3.
25. (new) An antibody or antibody fragment according to claim 21 wherein said peptide has an amino acid sequence comprising at least 10 contiguous amino acid residues of SEQ ID NO: 2.
26. (new) The antibody according to claim 21 which is a monoclonal antibody or fragment thereof.
27. (new) The antibody according to claim 22 which is a monoclonal antibody or fragment thereof.

28. (new) The antibody according to claim 23 which is a monoclonal antibody or fragment thereof.
29. (new) The antibody according to claim 24 which is a monoclonal antibody or fragment thereof.
30. (new) A recombinant cell expressing the antibody according to any one of claims 21-29.
31. (new) An isolated antibody or antibody fragment which specifically binds an isolated mammalian protein having anti-angiogenic activity and that is a receptor for an N-terminal fragment of plasminogen comprising kringle domains 1-4 and/or 5 wherein said protein does not cleave plasminogen kringle domains and wherein said protein comprises an amino acid sequence encoded for by a nucleic acid molecule that binds under stringent conditions to the nucleotide sequence from position 2180-2608 of SEQ ID NO: 1.
32. (new) An isolated antibody or antibody fragment which specifically binds an isolated mammalian protein having anti-angiogenic activity and that is a receptor for an N-terminal fragment of plasminogen comprising kringle domains 1-4 and/or 5 wherein said protein does not cleave plasminogen kringle domains and wherein said protein comprises an amino acid sequence encoded for by a nucleic acid molecule that binds under stringent conditions to the nucleotide sequence from position 797-2824 of SEQ ID NO: 1.
33. (new) A method for treating an angiogenesis related disease or disorder comprising administering an effective amount of an antibody of any one of claims 21-29 or 31-32 to a patient in need thereof.